Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo

Singh, Tripti; Prasad, Ram; Katiyar, Säntosh K.

doi:10.4161/epi.23078

Cited by 61 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Singh et al reported that HDAC activity was significantly inhibited in both A549 and H1299 cells treated with honokiol. 44 HeLa cells treated with TSA and PdNPs exhibited significant inhibition of HDAC activity. 8 The results herein suggest that synthetic HDACIs such as TUB-A have promising therapeutic activity, especially in combination with PdNPs.…”

Section: Results and Discussion Synthesis And Characterization Of Pdnpsmentioning

confidence: 99%

Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

Yuan¹,

Peng²,

Gurunathan³

2017

IJN

View full text Add to dashboard Cite

Background Breast cancer is the most common malignant disease that occurs in women. Histone deacetylase (HDAC) inhibition has recently emerged as an effective and attractive target for the treatment of cancer. The aim of this study was to investigate the efficacy of a combined treatment of tubastatin A (TUB-A) and palladium nanoparticles (PdNPs) against MDA-MB-231 human breast cancer cells using two different cytotoxic agents that work by two different mechanisms, thereby decreasing the probability of chemoresistance in cancer cells and increasing the efficacy of toxicity, to provide efficient therapy for advanced stage of cancer without any undesired side effects. Methods PdNPs were synthesized using a novel biomolecule called R-phycoerythrin and characterized using various analytical techniques. The combinatorial effect of TUB-A and PdNPs was assessed by various cellular and biochemical assays and also by gene expression analysis. Results The biologically synthesized PdNPs had an average size of 25 nm and were spherical in shape. Treatment of MDA-MB-231 human breast cancer cells with TUB-A or PdNPs showed a dose-dependent effect on cell viability. The combination of 4 μM TUB-A and 4 μM PdNPs had a significant inhibitory effect on cell viability compared with either TUB-A or PdNPs alone. The combinatorial treatment also had a more pronounced effect on the inhibition of HDAC activity and enhanced apoptosis by regulating various cellular and biochemical changes. Conclusion Our results suggest that there was a strong synergistic interaction between TUB-A and PdNPs in increasing apoptosis in human breast cancer cells. These data provide an important preclinical basis for future clinical trials on this drug combination. This combinatorial treatment increased therapeutic potentials, thereby demonstrating a relevant targeted therapy for breast cancer. Furthermore, we have provided the first evidence for the combinatorial effect and mechanism of toxicity of TUB-A and PdNPs in human breast cancer cells. The novelties of the study were identification of a combination therapy that consists of suitable therapeutic molecules that kill cancer cells and also exploration of two different possible mechanisms involved to reduce chemoresistance in cancer cells.

show abstract

Section: Results and Discussion Synthesis And Characterization Of Pdnpsmentioning

confidence: 99%

Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

Yuan¹,

Peng²,

Gurunathan³

2017

IJN

View full text Add to dashboard Cite

show abstract

“…Honokiol (HK), a lignanoid extracted from Magnolia officinalis or other species of Magnoliaceae, can inhibit the transfer and proliferation, promote differentiation, and induce apoptosis of tumor cells, as well as inhibit tumor angiogenesis (Deng et al, 2008;Hahm, Karlsson, Bonner, Arbiser, & Singh, 2014;Liang et al, 2010;Singh, Prasad, & Katiyar, 2013). Nevertheless, the poor water solubility of HK limits its clinical application.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells

Zhang

Chen

Yuan

et al. 2015

Carbohydrate Polymers

View full text Add to dashboard Cite

“…Many species of Magnolia are traditionally used in Asian medicine, mainly its neolignan honokiol, extracted from the bark and the leaves of the tree. Honokiol is able to induce apoptosis and cell cycle arrest in non-small cell lung cancer [54] and in adult Tcell leukemia [55]. Recently it has been demonstrated that other natural compounds extracted from plants, such as green tea polyphenols and curcumin, exert their anti-cancer properties through the inhibition of the HDAC activity [56,57].…”

Section: Lignans Isolated From Plantsmentioning

confidence: 99%

Natural Compounds: Molecular Weapons against Leukemia’s

Taverna¹,

Corrado

2017

J Leuk

View full text Add to dashboard Cite

Nowadays cancer is one of the main reasons of death all over the world and it is estimated that deaths caused by cancer will grow dramatically in the next decades. Even if chemotherapy is the election therapy for solid tumors, as well as leukemias and lymphomas, cancer treatments are in continuous evolution trying to solve the problem of resistance mainly due to low accumulation of the drug in tumor cells (MDR). Natural compounds represent a valid alternative to treat several disease and recently the scientific community focus on these natural compounds and plant metabolites with therapeutic activities and low toxicities compared with synthetic ones.A combination therapy, that join conventional chemotherapy with natural plant metabolites, is now considered a new promising strategy to overcome MDR and reduce cellular toxicity; in particular, in leukemia due to its very complex origin and development of leukemogenesis.Here, we want to summarize and update the recent applications of natural compounds in the treatment of leukemia.

show abstract

Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo

Cited by 61 publications

References 41 publications

Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells

Natural Compounds: Molecular Weapons against Leukemia’s

Contact Info

Product

Resources

About